Menu
April 26, 2021

Blood Clots and Reports of Blindness Following Experimental COVID Vaccines

Overview

Expert doctors and scientists issued early warnings to the FDA, vaccine manufacturers, and the press, attempting to avert the tragedy of life-threatening and fatal blood clots in COVID vaccine recipients, we are now witnessing. We review chronology of events of the red-hot topic of blood clots and regulatory agency reviews of experimental COVID vaccines as they unfolded around the world. We revisit highlights of the wise counsel of our expert doctors and scientists whose forewarnings were ignored. We reveal the latest VAERS reports on cases of blood clots following administration of Pfizer, Moderna, and J&J’s vaccines. We explore background and search of VAERS, UK and European governmental agency reports of scarcely discussed issue of vascular-related blindness, which mysteriously is not being reported in the media… all in today’s article.

By Dawn Amittai

 

Reports of Life-Threatening and Fatal Blood Clots Following Experimental AstraZeneca and J&J Vaccines Flood the News

During the past few months, the media has been flooded with reports of life-threatening and fatal blood clots occurring in experimental COVID vaccine recipients. Sadly, expert doctors and scientists who foresaw this devastating possibility, in an attempt to avert a tragedy, issued early warnings to the FDA, vaccine manufacturers, and the press. Their sage counsel was simply ignored by our public health authorities and regulatory agencies. We will revisit some highlights of their wisdom shared in our earlier articles, to provide greater understanding of what they foretold as underlying triggers which could cause these catastrophic injuries we are now witnessing. First, we will review the events of the past few months on the red-hot topic of blood clots, as they unfolded around the world, and then we will explore a scarcely discussed issue of vascular-related (i.e., vessels of the body that carry fluids) blindness, which mysteriously is not being reported in the media.

In early March, reports that AstraZeneca’s COVID vaccine could be causing blood clots began appearing in the news. Austria temporarily suspended use of the AstraZeneca jab as a precaution after the Federal Office for Safety in Health Care (BASG) received reports of a temporal connection with serious blood clots in two vaccine recipients. A 49-year-old woman died from severe coagulation disorders and a 35-year-old woman developed a life-threatening pulmonary embolism (blood clot in the lung). This was followed by Denmark becoming the first country to outrightly suspend use of the AstraZeneca jab, quickly followed by many other countries delaying their rollout or suspending the vaccine’s use. At that time, AstraZeneca’s response was, “More than 17 million people have received the vaccine in the United Kingdom and the European Union to date [through the second week of March], with fewer than 40 cases of blood clots.”

The European Medicines Agency’s (EMA) safety committee, Pharmacovigilance Risk Assessment Committee (PRAC) concluded that “…unusual blood clots with low blood platelets should be listed as very rare side effects…” of AstraZeneca’s COVID vaccine. They added, “The PRAC noted that the blood clots occurred in veins in the brain (cerebral venous sinus thrombosis, CVST) and the abdomen (splanchnic vein thrombosis) and in arteries, together with low levels of blood platelets [blood cells which form clots to stop bleeding] and sometimes bleeding.” PRAC acknowledged that as of April 4th, 169 cases of CVST and 53 cases of splanchnic vein thrombosis had been reported to EudraVigilance; the majority of cases occurred in women under the age of 60, but admitted they had not yet established any means of identifying specific risk factors. The EMA’s bottom line conclusion: “The benefits of the vaccine continue to outweigh the risks for people who receive it.” Interesting to note that the director of the World Health Organization (WHO) firmly supported the continued use of AstraZeneca’s vaccine, explaining that its vaccines advisory committee found no causal link between the vaccine and blood clots…

Following the saga of AstraZeneca’s vaccine, similar reports of serious injuries and deaths related to blood clots in recipients of the Johnson & Johnson (J&J) COVID vaccine surfaced… like an eerie sense of déjà vu. Initially six — now up to fifteen — cases of women between the ages of 18 and 48 developed CVST within one to three weeks of vaccination. According to information from the CDC, there have been three deaths to date: A 45-year-old woman in Virginia, a woman in her 50’s from Oregon, and details of the third death have not yet been released.  Emma Burkey, an 18-year-old Clark County high school senior was reported in the news this week as one of the initial six women who experienced serious blood clotting following the J&J COVID vaccine. Emma suffered seizures and blood clots in the brain after receiving the jab earlier this month, and remains hospitalized following three brain surgeries.

Scientists in Germany and Norway published studies in the New England Journal of Medicine which hypothesized that some people who received the experimental AstraZeneca shot are experiencing an abnormal immune system response, forming antibodies that attack their own platelets. It is not yet clear whether this is the same case with the J&J jab, but both employ the same technology. AstraZeneca and J&J’s experimental shots both use a brand new technology called a “viral vector vaccine” which introduces a coronavirus gene to the body using a genetically engineered common-cold virus; neither employ the new mRNA technology utilized by Moderna and Pfizer. “Suspicion is rising that these rare cases may be triggered by the adenovirus component of the AstraZeneca and J&J vaccines,” said Eleanor Riley, a professor of immunology and infectious diseases at the University of Edinburgh

US Pauses Administration of J&J’s Experimental Vaccine

These events led up to the Centers for Disease Control (CDC) and Food and Drug Administration (FDA) issuing a joint statement on Johnson & Johnson’s COVID-19 vaccine on April 13, 2021, after 6.8 million doses had been administered in the US. On April 14th, the Advisory Committee on Immunization Practices (ACIP) upheld the pause, after holding a four-hour emergency meeting. ACIP postponed their vote, promising to reconvene in a week to 10 days; in the meantime the pause was extended pending further analysis of data related to blood clots. ACIP reconvened on April 23, and the FDA and CDC announced that they “… have determined that the recommended pause regarding the use of the Janssen (Johnson & Johnson) COVID-19 Vaccine in the US should be lifted and use of the vaccine should resume.” CDC director Rochelle Walensky said during a news briefing, “The American public should feel reassured about the safety systems and protocols we have in place around the COVID-19 vaccines.”

Meanwhile — “déjà vu all over again” — in Europe, the EMA found a “possible link” between the J&J COVID vaccine and occurrences of these blood clots in the brain. After examining a small number of these cases in J&J vaccine recipients in the US, they concluded the vaccine’s benefits still outweighed the risks. Their safety committee, PRAC, recommended a warning should be added to the product label. J&J immediately announced it will revise its label to include important information on the diagnosis and management of this adverse event, and resume vaccine shipments to the European Union (EU), Norway, and Iceland. Widespread use of the shot in Europe has not yet started, and many countries said they would move forward with their J&J immunization rollout.

Blood Clotting Injuries Also Reported to VAERS with Moderna and Pfizer COVID Vaccines: Why is this Being Denied by the CDC?

Although the issue of blood clotting has focused on AstraZeneca and J&J’s experimental shots, there is also some discussion — and evidence from the VAERS — that Moderna and Pfizer’s mRNA jabs have accrued similar reports from their vaccine recipients. Following the decision to put the J&J jab on pause, the CDC website published “J&J/Janssen Vaccine Pause Questions and Answers” which included the question and answer posted below (see screen shot):

Although the CDC has flatly denied that these blood clotting (i.e., CVST and splanchnic vein thrombosis) events are occurring in both Moderna and Pfizer vaccine recipients, the documented occurrence of this reaction is easily proven to be true. In her recent article, “J&J Vaccine Paused; Meeting Materials about Serious Adverse Events Unavailable,” Alix Mayer investigated this by performing a search of the VAERS reports. Although it is well known that VAERS only captures a tiny percentage of the actual injuries and deaths reported after vaccine administration, her search revealed two reports of cerebral venous thrombosis for J&J and two for Moderna. She then searched for a general report in VAERS of “embolic and thrombotic events, venous” (i.e., life-threatening blood clots in the venous system), which revealed 303 total events as of April 8, 2021, the majority of which were reported following Pfizer and Moderna shots, with far fewer for J&J’s jab. Her conclusion: “…it is difficult to understand why J&J has been singled out for a pause.”

We ran an updated VAERS search with the same criteria (i.e., embolic and thrombotic events, venous), using current data through April 16, 2021. It now shows a total of 480 cases: 77 reports for J&J vaccine recipients, 252 cases for Moderna, and 227 cases for Pfizer/BioNTech. *  This represents an overall increase from 303 total reports last week, to 480 cases — an additional 177 of these life-threatening adverse events in one single week. We should always remember, the number of cases reported to VAERS represents only 1% of all the actual vaccine adverse events and 1-13% of serious adverse events/deaths (see VAERS data).

“Embolic and Thrombotic Events, Venous” Reported to VAERS

by April 16, 2021 for Pfizer, Moderna and J&J’s COVID Vaccines: 480 cases

*Because some cases have multiple vaccinations and symptoms, a single case can account for multiple entries in this table; this is the reason why this report from VAERS shows the total count is greater than 707 and the total percentage is greater than 100.

 

A Broader Search for “Embolism and Thrombosis” Events Reported to VAERS by April 16, 2021 for Pfizer, Moderna and J&J’s COVID Vaccines

Based upon the large number of additional cases of venous blood clotting events reported to VAERS in one week, we decided to further broaden and generalize the search to include all “embolic and thrombotic events” (i.e., not limiting the search to only venous events). Using MedDRA, a highly specific standardized medical terminology provided by VAERS — this broader category includes the following injuries (see screen shot):

 

 

In this much broader search VAERS found a total of 707 cases reported by April 16, 2021 (see VAERS data above) * Again, it is important to remember that these reported cases represent only a very small fraction of the actual number of occurrences. The breakdown of reported events by COVID vaccine manufacturer is:

  • 347 blood-clotting events were reported to VAERS after Pfizer injections (49% of total cases)
  • 334 blood-clotting events were reported to VAERS after Moderna shots (47% of total cases)
  • 131 blood-clotting events were reported to VAERS after J&J jabs (18% of the total cases)
  • Permanent disability: A separate search of VAERS data showed that 83 of the 707 total cases resulted in permanent disability (it is likely that many of these reported injury cases are still unresolved or the outcomes are not yet known)

We also ran a separate query which showed 111 of the 707 vaccine recipients who experienced these life-threatening blood clotting injuries died. The breakdown by vaccine manufacturer is:

  • 59 of these deaths followed Pfizer/BioNTech shots (52% of total deaths)
  • 55 who died had received Moderna jabs (49% of total deaths)
  • 19 of the deaths were J&J vaccine recipients (17% of the total deaths)

 *Because some cases have multiple vaccinations and symptoms, a single case can account for multiple entries in this table; this is the reason why this report from VAERS shows the total count is greater than 707 and the total percentage is greater than 100.

We examined the number of blood clotting cases reported to VAERS for each of the three different COVID vaccines. We then calculated the corresponding percentage for each of the three COVID jabs, from the total number of vaccines administered in the US by April 16th (see CDC’s Covid Tracker). Here is what we found:

  • Moderna vaccine recipients’ blood clotting cases accounted for 47% of the total cases after 89M shots were administered; Moderna jabs account for 44% of total jabs given.
  • J&J vaccine recipients’ blood clotting cases accounted for 18.5% of the total cases after only 7.8M shots were administered; J&J jabs account for only 4% of total jabs given.

This analysis reveals a disproportionately large number of these cases followed J&J’s jabs. While J&J’s vaccines account for only 4% of the total number of all three COVID vaccines administered in the US by April 16th, 18.5% of these life-threatening blood clotting events reported occurred in recipients of their injection.

Based on these current VAERS reports, we have established that blood clotting adverse events in the US following the administration of these experimental COVID vaccines have been reported with all three experimental shots.  However, our simple analysis of the VAERS data confirms a larger proportion of these injuries were reported following the J&J jab.

Considering that the CDC and FDA have now lifted the pause on J&J’s jab, and have recommended immediate resumption of its administration, can we really believe their April 23rd statement, “…this vaccine is safe and effective…”?  Can we really trust J&J — with their vast criminal rap sheet — when they reassure us, “The safety and well-being of the people who use our products is our number one priority”? With 707 reports of vaccine recipients experiencing life-threatening, disabling, and fatal embolic and thrombotic injuries — 83 of which resulted in permanent disability and 111 in death — what will it take for our medical experts and regulatory agencies to judiciously investigate the safety of all three of these experimental COVID vaccines?

***

Vision Loss Following Experimental COVID Vaccinations: Exploring Reports from Governmental Vaccine Adverse Reaction Reporting Agencies Around the World

Over the past few months, we have been seeing a myriad of media reports of blood clots in the brain following administration of these COVID vaccines. However, as we have seen in our search of blood clotting injuries reported by VAERS to date, the brain is certainly not the only region where they have occurred. In fact, blood clots can result in devastating injuries almost anywhere in the vasculature (blood vessels in the body) of the body.

If clots occur in areas of the brain (i.e., “stroke”) responsible for sight, or in the microvasculature (tiny blood vessels which distribute blood within our tissues) of the eye, they can even cause loss or serious impairment of vision. Although reports of injuries involving partial or complete visual loss following these vaccines have yet to appear in the media — aside from unsubstantiated reports in social media — it turns out that quite a large number of of them have been reported to various corresponding governmental regulatory agencies including VAERS, UK Yellow Card Scheme, and European EudraVigilance. The sheer number of worldwide reports of visual injuries occurring in COVID vaccine recipients grabbed our attention — particularly at this time when blood clots are such a red-hot topic. We concluded that this scarcely reported issue deserved exploration — and the results of our investigation follow.

Limitations Inherent in Employing Data from Various Governmental Reporting Agencies

With that said, while doing an exploration of this nature, it is important to keep the limitations of these governmental vaccine adverse event reporting and tracking systems in mind. VAERS even details its own limitations: “The number of reports alone cannot be interpreted or used to reach conclusions about the existence, severity, frequency, or rates of problems associated with vaccines… data are subject to limitations of under-reporting, reporting bias, and lack of incidence rates in unvaccinated comparison groups.” VAERS is “not designed to assess causality.” In fact, each of the various governmental reporting sites listed previously, presents a comparable disclaimer statement. Thus, it is always good to consider the injuries are temporally related to these experimental shots; we cannot claim a definite causal relationship.

To add to that, we know that VAERS website data is almost never current — reported adverse events and deaths are often backlogged; we are not as familiar with how other reporting agencies in UK, and Europe maintain their data.  And finally, we know that the number of cases reported to VAERS account for fewer than 1% of all the actual vaccine adverse events and only 1-13% of serious events/deaths are reported. However, outside of VAERS, we lack data on what the percentage of cases reported to UK Yellow Card and European EudraVigilance systems represents in terms of the actual cases that have occurred. Thus, it is difficult to ascertain highly accurate rates of adverse event occurrence based on their reports. Despite these challenges, we will focus our exploration on cases of vascular-related visual impairment or total loss which have occurred in experimental COVID vaccine recipients, and which have been reported to one of these various vaccine adverse event tracking systems since the rollout began late last year.

Remember the Early Warnings about Blood Clots from Concerned Experts?

Before going directly into the data, it will be helpful to revisit some of the wisdom issued previously by our medical specialists, so we can gain a basic and more meaningful understanding of the possible underlying mechanisms causing these blood clots. What do these clotting injuries have in common with the forewarnings of these concerned physicians and scientists?  Let us briefly highlight some of the discussion from previous articles, where they predicted the possibility that these experimental COVID vaccines could cause inflammation of the brain, and result in life-threatening blood clot formation.

In early December of 2020, J. Patrick Whelan, M.D. PhD, a pediatric specialist caring for children with multisystem inflammatory syndrome (MIS), expressed his concerns in a warning letter to the FDA about the Moderna and Pfizer COVID vaccines: “I am concerned about the possibility that the new vaccines aimed at creating immunity against the SARS-CoV-2 spike protein (including the mRNA vaccines of Moderna and Pfizer) have the potential to cause microvascular injury to the brain, heart, liver, and kidneys in a way that does not currently appear to be assessed in safety trials of these potential drugs.”

Similar concerns were echoed by Hooman Noorchashm, M.D., Ph.D., a physician-scientist specialist in cardiothoracic surgery, who wrote a warning letter to FDA regulators, Pfizer leaders and the press on January 26th,, 2021. He expressed his concern that patients who have had a recent COVID-19 infection and receive a COVID vaccine, could be likely to suffer from autoimmune attacks along the ACE-2 receptors present in the heart, and in the microvasculature of the brain, liver and kidney. Dr. Noorchashm explained — similarly to the German and Norwegian scientists who very recently published studies on this topic (previously mentioned) in the New England Journal of Medicine — when the immune system attacks those tissues, it generates inflammation, which can lead to clot formation, and result in heart attacks, strokes, and so on.

Types of Vision Injuries Reported to Governmental Agencies by Experimental COVID Vaccine Recipients

What are some of the actual visual injuries following COVID vaccine administration being reported to these regulatory agencies? As mentioned previously, many eye/vision injuries are microvascular events, which by definition are caused by inflammation and formation of small blood clots; examples include conditions such as retinal artery occlusion, retinal vein thrombosis. Other injuries resulting in vision loss can be caused by strokes, involving damage to brain cells in areas of the brain responsible for sight. Strokes can be either “ischemic” (i.e., caused by blood clots blocking blood flow to brain cells) or “hemorrhagic” (i.e., caused by bleeding into an area(s) damaging brain cells). Thus, reported injuries to sight can also be hemorrhagic events (i.e., from bleeding instead of clots) — such as retinal aneurysm or hemorrhagic strokes occurring in areas of the brain which can cause sudden blindness — partial or total. For our exploration, we decided to include all vascular injuries — i.e., blood clots or bleeding — related to loss or impairment of vision following one of the experimental COVID injections.

Getting Down to the Data: Visual Loss or Impairment Following Experimental COVID Vaccinations

We will begin with presenting the number of cases of adverse events involving primarily vascular-related visual impairment or loss that were reported to VAERS, followed by data sourced from UK’s Yellow Card and European EudraVigilance systems.

Vascular-Related Visual Impairment/Loss Adverse Events Reported to VAERS by April 16, 2021 for Pfizer, Moderna and J&J COVID-19 Vaccines: 495 cases

Bearing in mind the intrinsic limitations of VAERS previously detailed, let us explore the number of their reports involving vascular eye injuries which resulted in partial or complete loss of vision (see VAERS data):

A total of 495 adverse events (AEs) were reported to VAERS by April 16th which involved vascular-related visual impairment or loss: * As always, we can put this into perspective knowing that these reports represent only a small fraction (i.e., 1 to 13%) of the actual events. The breakdown of these events by COVID vaccine manufacturer is:

  • 233 vision-related AEs were reported to VAERS after Pfizer injections (47%)
  • 209 vision-related AEs were reported to VAERS after Moderna injections (42%)
  • 80 vision-related AEs were reported to VAERS after J&J injections (16%)
  • Deaths: A separate VAERS search revealed that of the 495 total cases, 6 resulted in death (1 following a J&J’s jab and 5 following Moderna’s)
  • Permanent disability: Another separate search of VAERS data showed that 67 of the 495 total cases resulted in permanent disability (again, it is likely that many of these reported injury cases are still unresolved or the outcomes are not yet known).

* Because some cases have multiple vaccinations and symptoms, a single case can account for multiple entries in this table; this is the reason why this report from VAERS shows the total count is greater than 707 and the total percentage is greater than 100.

It is interesting to note that these vascular-related eye injuries occurred far more frequently in the younger age groups: the majority, 39%, occurred in the 17 to 44-year-old age group, followed by 31% in the 44 to 65 age group, and 27% in those 65 years of age and older. Also, a similar pattern of distribution — seen earlier in the broad VAERS report of “Embolism and Thrombosis” — revealed itself here. Considering the total number of vaccines administered in the US by the date of this VAERS report (April 16th), a disproportionately large number of these cases followed J&J’s jabs. While J&J’s shots account for only 4% of the total number of all three COVID vaccines administered in the US by April 16th (see previous graph “CDC’s COVID Tracker”), 16% of the vascular-related vision loss events reported were from recipients of the J&J vaccine.

Some individual case descriptions of visual impairment/loss reported in VAERS are:

  • 34-year-old male from California: “01/31/21 approx. 12 hours after receiving the second dose of Moderna vaccine I experienced blurred vision to right eye. Upon further eval I confirmed 30% loss of vision to right eye. No other symptoms noted. To date no change in symptoms. Since onset of symptoms, I have been evaluated by various providers. 02/03 MD, 02/04 MD, 02/04 emergency room intake with blood work and MRI at hospital, 02/12 MD.”
  • 76-year-old male from Michigan: “Right eye Central Retinal Artery Occlusion resulting in blindness in right eye. Sight lost suddenly. Hospitalized for stroke assessment.”
  • 86-year-old male from California: “Vaccine admin Wed 3 pm. Thurs no problem. Friday am patient woke up almost fully blind right eye.”
  • 33-year-old female from Alabama: “Won’t let me type everything. Long story short. Face tingled for a few days after shot, forehead skin got tight and dry, now I’ve lost vision in my right eye! Today is exactly 2 weeks after 1st vaccine and sight in my right eye is worse and painful.”
  • 91-year-old female from Pennsylvania: “Significant loss of vision R eye-awoke on Feb 6 and noted splotches in vision of R eye. Workup suggests compromised blood flow to that eye.”
  • 88-year-old female from Colorado: “Eye Stroke / Retinal Occlusion Lost eyesight in left eye”
  • 26-year-old male from New York: “Acute Optic neuritis bilaterally, initial symptoms started 24 hours after injection, became severe a week after injection (lost sight in left eye). I was admitted to the hospital 1/19/21 and given 1000mg of Prednisone daily from 19th to the 22nd.”
  • 52-year-old from Michigan: “Diagnosed day after 2nd shot with ophthalmic artery thrombus causing vision loss/change in left eye. I did get shot series on 12/22/2020 #1 and 1/10/2021 and was diagnosed with Covid-19 on 12/13/2020. My internist MD did not feel the vaccine caused the thrombus/stroke, but I wanted to report it as it was associated with the vaccine administration (symptoms of vision loss within 24 hours of the vaccine #2 administration).”
  • 83-year-old female from Indiana: “Moderna COVID-19 Vaccine At 2 PM I went blind in my left eye. Went to emergency room at Hospital Was told I have Blood clot in my eye causing the blindness and Ophthalmologist says it will probably be permanent.”
  • 47-year-old male from Indiana: “January 26th, eye exam, thought I had detached retina. Have vision loss in both eyes’ upper left quadrant. Had field test done at eye appointment, Dr. said both eyes were affected, and I had a stroke. January 26th in ER had CT scan. Admitted that evening had carotid ultrasound. January 27th, Echo and MRI with contrast. January 28th transesophageal echocardiogram.”

796 Cases of Vascular-Related Visual Loss/ Impairment Reported to UK’s Yellow Card Following Pfizer and AstraZeneca’s Experimental COVID Vaccinations

Next, we searched UK Yellow Card data through April 14, 2021; this revealed a total of 796 reported events of vascular-related visual impairment/loss for both Pfizer and AstraZeneca’s vaccines. Please note that we do not have data — as we do for VAERS — on what the percentage of cases reported to Yellow Card represents in terms of the actual cases which have occurred (See Yellow Card Scheme data reports):

A total of 495 adverse events (AEs) were reported to VAERS by April 16th which involved vascular-related visual impairment or loss: * As always, we can put this into perspective knowing that these reports represent only a small fraction (i.e., 1 to 13%) of the actual events. The breakdown of these events by COVID vaccine manufacturer is:

  • 233 vision-related AEs were reported to VAERS after Pfizer injections (47%)
  • 209 vision-related AEs were reported to VAERS after Moderna injections (42%)
  • 80 vision-related AEs were reported to VAERS after J&J injections (16%)
  • Deaths: A separate VAERS search revealed that of the 495 total cases, 6 resulted in death (1 following a J&J’s jab and 5 following Moderna’s)
  • Permanent disability: Another separate search of VAERS data showed that 67 of the 495 total cases resulted in permanent disability (again, it is likely that many of these reported injury cases are still unresolved or the outcomes are not yet known).

* Because some cases have multiple vaccinations and symptoms, a single case can account for multiple entries in this table; this is the reason why this report from VAERS shows the total count is greater than 707 and the total percentage is greater than 100.

It is interesting to note that these vascular-related eye injuries occurred far more frequently in the younger age groups: the majority, 39%, occurred in the 17 to 44-year-old age group, followed by 31% in the 44 to 65 age group, and 27% in those 65 years of age and older. Also, a similar pattern of distribution — seen earlier in the broad VAERS report of “Embolism and Thrombosis” — revealed itself here. Considering the total number of vaccines administered in the US by the date of this VAERS report (April 16th), a disproportionately large number of these cases followed J&J’s jabs. While J&J’s shots account for only 4% of the total number of all three COVID vaccines administered in the US by April 16th (see previous graph “CDC’s COVID Tracker”), 16% of the vascular-related vision loss events reported were from recipients of the J&J vaccine.

Some individual case descriptions of visual impairment/loss reported in VAERS are:

  • 34-year-old male from California: “01/31/21 approx. 12 hours after receiving the second dose of Moderna vaccine I experienced blurred vision to right eye. Upon further eval I confirmed 30% loss of vision to right eye. No other symptoms noted. To date no change in symptoms. Since onset of symptoms, I have been evaluated by various providers. 02/03 MD, 02/04 MD, 02/04 emergency room intake with blood work and MRI at hospital, 02/12 MD.”
  • 76-year-old male from Michigan: “Right eye Central Retinal Artery Occlusion resulting in blindness in right eye. Sight lost suddenly. Hospitalized for stroke assessment.”
  • 86-year-old male from California: “Vaccine admin Wed 3 pm. Thurs no problem. Friday am patient woke up almost fully blind right eye.”
  • 33-year-old female from Alabama: “Won’t let me type everything. Long story short. Face tingled for a few days after shot, forehead skin got tight and dry, now I’ve lost vision in my right eye! Today is exactly 2 weeks after 1st vaccine and sight in my right eye is worse and painful.”
  • 91-year-old female from Pennsylvania: “Significant loss of vision R eye-awoke on Feb 6 and noted splotches in vision of R eye. Workup suggests compromised blood flow to that eye.”
  • 88-year-old female from Colorado: “Eye Stroke / Retinal Occlusion Lost eyesight in left eye”
  • 26-year-old male from New York: “Acute Optic neuritis bilaterally, initial symptoms started 24 hours after injection, became severe a week after injection (lost sight in left eye). I was admitted to the hospital 1/19/21 and given 1000mg of Prednisone daily from 19th to the 22nd.”
  • 52-year-old from Michigan: “Diagnosed day after 2nd shot with ophthalmic artery thrombus causing vision loss/change in left eye. I did get shot series on 12/22/2020 #1 and 1/10/2021 and was diagnosed with Covid-19 on 12/13/2020. My internist MD did not feel the vaccine caused the thrombus/stroke, but I wanted to report it as it was associated with the vaccine administration (symptoms of vision loss within 24 hours of the vaccine #2 administration).”
  • 83-year-old female from Indiana: “Moderna COVID-19 Vaccine At 2 PM I went blind in my left eye. Went to emergency room at Hospital Was told I have Blood clot in my eye causing the blindness and Ophthalmologist says it will probably be permanent.”
  • 47-year-old male from Indiana: “January 26th, eye exam, thought I had detached retina. Have vision loss in both eyes’ upper left quadrant. Had field test done at eye appointment, Dr. said both eyes were affected, and I had a stroke. January 26th in ER had CT scan. Admitted that evening had carotid ultrasound. January 27th, Echo and MRI with contrast. January 28th transesophageal echocardiogram.”

 

796 Cases of Vascular-Related Visual Loss/ Impairment Reported to UK’s Yellow Card Following

Next, we searched UK Yellow Card data through April 14, 2021; this revealed a total of 796 reported events of vascular-related visual impairment/loss for both Pfizer and AstraZeneca’s vaccines. Please note that we do not have data — as we do for VAERS — on what the percentage of cases reported to Yellow Card represents in terms of the actual cases which have occurred (See Yellow Card Scheme data reports):

 Pfizer BioNTech COVID Vaccine: Visual Impairment/Loss Vascular-Related Adverse Events Reported to UK Yellow Card System by April 14, 2021: 192 cases

 Pfizer BioNTech COVID Vaccine: Visual Impairment/Loss Vascular-Related Adverse Events Reported to UK Yellow Card System by April 14, 2021: 192 cases

In the most recent UK Yellow Card weekly summary report dated April 14, 2021, we found a combined total of approximately* 796 cases of vascular-related vision injuries, none of which resulted in death. The UK Yellow Card system does not provide demographic data in their specific medical condition summary reports. Thus, this information is not available for further exploration and reporting.

*UK Yellow Card data is comprised of weekly summary reports, grouping disorders into classifications which may include a few conditions (e.g., night blindness, transient blindness, central vision loss) which do not precisely match our search for only vascular-related cases.

 

13,719 Cases of Vascular-Related Visual Loss/Impairment Reported to Europe’s EudraVigilance Following Pfizer, Moderna, AstraZeneca, and J&J’s Experimental COVID Vaccinations

Next, we searched for vascular-related visual impairment/loss adverse events reported to the European EudraVigilance System by April 24, 2021 (the most recent data they reported) for Pfizer, AstraZeneca, Moderna and J&J’s experimental COVID vaccines. Again, please note that we do not have data — as we do for VAERS — on what the percentage of cases reported to EudraVigilance represents in terms of the actual cases which have occurred (see EudraVigilance data):

Pfizer’s COVID Vaccine: Visual Impairment/Loss Vascular-Related Adverse Events Reported to European EudraVigilance System by April 24, 2021: 4,817 cases

 

AstraZeneca’s COVID Vaccine: Visual Impairment/Loss Vascular-Related Adverse Events Reported to European EudraVigilance System by April 24, 2021: 8,293 cases

 

Moderna’s COVID Vaccine: Visual Impairment/Loss Vascular-Related Adverse Events Reported to European EudraVigilance System by April 24, 2021: 588 cases

 

J&J’s COVID Vaccine: Visual Impairment/Loss Vascular-Related Adverse Events Reported to European EudraVigilance System by April 24, 2021: 21 cases

 

The search of European EudraVigilance data for vision loss adverse events, revealed a combined total of 13,719 vascular-related cases, 14 of which resulted in death: 6 following Pfizer’s jabs, 3 after Moderna’s, and 5 after AstraZeneca’s. A clear pattern emerged, revealing a far greater number of these adverse events reported in women, and in the 18- to 64-year-old age group.

***

 

Our exploration has substantiated that blood clots are indeed a life-threatening, potentially disabling, and even fatal injury which has been reported following the administration of all four experimental COVID vaccines. Despite the recent “pauses” on administration of several of these vaccines, governmental public health and regulatory agencies around the world continue to reassure us that these vaccines are “safe and effective” (see CDC statement) and encourage us to “… get a COVID-19 vaccine as soon as you are eligible.” Some of these are the very agencies which we know were forewarned of the possibility of these catastrophic injuries that we are now witnessing. Why did they ignore these early warnings from our concerned expert doctors and scientists? Why do they appear to underestimate the tragic consequences of continuing to administer these experimental vaccines in the face of so much evidence of their potential for devastating outcomes? Do the benefits of these experimental COVID injections really outweigh the risks, as the CDC and FDA assure us?

Further, as our wider exploration of vascular-related injuries has revealed, we have ascertained that many adverse events of vision loss and impairment following experimental COVID vaccines have been reported to corresponding governmental regulatory agencies in many countries around the world. Is it not extraordinary that these injuries are not being reported in the news or publicized by concerned medical experts or public health authorities? One might even ponder, “What could possibly be the reason for this?” 

 

***

 

This article contains a growing list of deaths and serious injuries that occurred after the experimental COVID vaccines were administered. The death and serious injury reports are culled from the media, from the CDC’s Vaccine Adverse Event Reporting System (VAERS), as well as reporting systems outside the US. Although the deaths and serious injuries are temporally related to the COVID vaccination, Children’s Health Defense – California Chapter cannot claim the COVID vaccine definitively caused the deaths or serious injuries. That said, the symptom patterns and timing are highly suspicious, and tend to follow patterns of adverse events widely recognized to occur after other vaccinations. The adverse event and death reports serve as anecdotes that may soon establish a pattern. Children’s Health Defense – California Chapter is providing regular updates on newly reported injuries and deaths that occur after COVID vaccination. As always, Children’s Health Defense – California Chapter supports fully informed consent and no medical mandates. This is not medical advice. Please share this information with, and consult your doctor.